以amyloid-β 聚集為目標的阿茲海默氏症治療策略

dc.contributor.author黃鉦翔zh_tw
dc.contributor.author林志信zh_tw
dc.contributor.author李承榆zh_tw
dc.contributor.author簡虹琪zh_tw
dc.contributor.author陳廷碩zh_tw
dc.contributor.author李琦玫zh_tw
dc.contributor.author李桂楨zh_tw
dc.contributor.authorChen-Hsiang Huang, Chih-Hsin Lin, Cheng-Yu Lee, Hong-Chi Chien, Ting-Shou Chen, Chi-Mei Lee, Guey-Jen Lee-Chenen_US
dc.date.accessioned2019-08-12T04:47:50Z
dc.date.available2019-08-12T04:47:50Z
dc.date.issued2013-??-??
dc.description.abstract阿茲海默氏症是最常見的漸進性的認知能力下降和記憶力減退的失智症,病理上此疾病的特點是細胞外Aβ 胜肽的類澱粉斑塊沉積和細胞內神經纖維糾結。已知類澱粉沉積會增加氧化壓力、細胞興奮性毒性、能源消耗和細胞凋亡,最後導致神經細胞死亡。先前Aβ42-GFP 融合蛋白的研究顯示,Aβ42 胜肽的聚集可反應在相連的GFP 蛋白之綠螢光亮度上。故本研究建立表現Aβ42-GFP 融合蛋白的Tet-On 293 細胞作為篩檢平台,藉測定綠螢光亮度增加情形,來檢測可延緩或抑制Aβ 聚集的抑制物。首先檢測作為正控制組的薑黃素,可顯著增加綠螢光亮度。進一步以工研院提供的植物藥前處理細胞8 小時後誘導Aβ42-GFP 表現三天,發現NTNU-043、057、059、071 等植物藥可顯著增加綠螢光亮度,並伴隨著伴隨蛋白HSPB1 表現的增加。我們的結果顯示上述植物藥可抑制Aβ 聚集及其可能的機制,此篩檢平台可用來篩檢更多有潛能治療阿茲海默氏症的植物藥。zh_tw
dc.description.abstractAlzheimer’s disease (AD) is the most prevalent form of dementia associated with progressive cognitive decline and memory loss. Molecular hallmarks of the disease are characterized by extracellular Aβ plaques and intracellular neurofibrillary tangles (NFTs). Aβ deposition causes neuronal death via a number of possible mechanisms including oxidative stress, excytotoxicity, energy depletion and apoptosis. Previously Aβ42 was fused to the N-terminus of GFP to couple the aggregation state with the fluorescence of GFP. In the present study, Aβ42-GFP are used to generate Tet-On 293 cell clone as screening platforms. Inhibitors that retard or block Aβ aggregation can be distinguished by increasing fluorescence on Tet-On 293 cells. As a positive control, curcumin increased green fluorescence significantly. Treatment of herbal medicines NTNU-043, 057, 059 and 071 (provided by Industrial Technology Research Institute of Taiwan) resulted in significant increased fluorescence on Tet-On Aβ-GFP cells, accompanying with enhanced HSPB1 chaperone expression. Our results demonstrate how these herbal medicines are likely to work on Aβ-aggregation reduction, and provide insight into the possible working mechanism in AD. We anticipate our assay to be a starting point for screening more potential herbs for the treatment of AD.en_US
dc.identifier90359732-4EFA-B6CB-4ACC-482BD0733C21
dc.identifier.urihttp://rportal.lib.ntnu.edu.tw:80/handle/20.500.12235/80679
dc.language中文
dc.publisher國立臺灣師範大學生命科學學系zh_tw
dc.publisherDepartment of Life Science, NTNUen_US
dc.relation48,55-62
dc.relation.ispartof生物學報zh_tw
dc.subject.other阿茲海默氏病zh_tw
dc.subject.other類澱粉聚集zh_tw
dc.subject.other細胞模式zh_tw
dc.subject.other植物藥篩檢zh_tw
dc.subject.otherAlzheimer’s diseaseen_US
dc.subject.otherAβ aggregationen_US
dc.subject.othercell modelen_US
dc.subject.otherherbal medicine screenen_US
dc.title以amyloid-β 聚集為目標的阿茲海默氏症治療策略zh-tw
dc.title.alternativeTherapeutic Strategy Targeting Amyloid-β Aggregation for Alzheimer’s Diseasezh_tw

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ntnulib_ja_C0401_4801_055.pdf
Size:
950.38 KB
Format:
Adobe Portable Document Format

Collections